Will 2 February target for Ampligen US verdict be a 'Groundhog Day' scenario?
This article was originally published in Scrip
Executive Summary
Pennsylvania biotech Hemispherx Biopharma is likely keeping its fingers crossed the 2 February "Groundhog Day" action date set by the US FDA for its verdict on Ampligen, an experimental chronic fatigue syndrome (CFS) therapy, does not take the same path as the iconic Bill Murray weatherman character in the 1993 film – trusting the current review will be the last for the application, without another repeat in store.